PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

NCT00313482 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

35

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Hormone Refractory Prostate Cancer

Interventions

DRUG: Sargramostim
DRUG: Docetaxel
DRUG: Prednisone

Sponsor

Veeda Oncology

Collaborators

[object Object]